Last reviewed · How we verify
Systemic treatment
At a glance
| Generic name | Systemic treatment |
|---|---|
| Also known as | no intervention, Bevacizumab in combination with fluoropyrimidine-based schedules |
| Sponsor | Peking Union Medical College Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (PHASE3)
- Pre-Post Multimodal Assessment Of Severe Psoriasis Vulgaris Using Clinical, Dermoscopic And QoL Measures
- A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC Patients
- Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (NA)
- Iadademstat + SBRT With Atezo in ES-SCLC (PHASE1)
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia (PHASE2)
- A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Systemic treatment CI brief — competitive landscape report
- Systemic treatment updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI